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Case scenario 
JS, a 34-year-old contractor, presented with a two day history 
of a sore throat.  He was noted to have become increasingly 
centrally obese since his last visit – which he blamed on having 
gotten married in the interim – and was known to be a smoker. 
JS’ sore throat was his priority. However, a family history of 
diabetes mellitus and his history of ‘borderline’ hypertension 
were of more concern to his doctor. 
 Is this the metabolic syndrome? How should this patient 
be managed?
With a name as elusive as Syndrome X, it is all too easy 
to dismiss the topic as a rather exotic phenomenon for the 
internists and researchers to deal with. Nevertheless, what 
was described as Syndrome X in 1988 by Gerald Reaven and 
is now referred to as  metabolic syndrome, appears to be one 
of the commonest conditions encountered in general practice. 
The metabolic syndrome, being a syndrome should innately be 
a collection of signs and symptoms of a pathological process 
together constituting a picture of a particular clinical condition 
warranting particular management.  The gist of it all can be 
seen to lie in different perspectives; the metabolic syndrome 
can be seen as:
• ‘simply’ a clustering of cardiovascular risk factors 
– possibly preventable and treatable or, 
• a multiplex of metabolic risk conditions namely 
atherogenic dyslipidaemia, hypertension, glucose 
intolerance, a proinflammatory and a prothrombotic 
state.  This offers, perhaps, a more pathophysiological 
description of the condition. 
When it comes to the young gentleman described above, 
dismissing his possible collection of risk factors or failing to give 
them their due importance can result in the loss of a precious 
opportunity at preventive care which is definitely neither exotic 
nor beyond the scope of the primary care physician.
The definition
  In 2004 the International Diabetes Federation (IDF) 
revised its definition of Metabolic Syndrome.2  According to this 
new definition, for a person to be defined as having the metabolic 
syndrome they must have central obesity (ethnicity specific 
values as outlined in Table 1) plus 2 of any of the following 4 
factors:
• Elevated triglyceride: > 1.7 mmol/L or specific 
treatment for this lipid abnormality
• Decreased HDL:  < 1.03 mmol/L in males; < 1.29 
mmol/L in females.
• Elevated blood pressure:  Systolic ≥ 130 mmHg; 
diastolic ≥ 85 mmHg or on antihypertensive therapy
• Increased fasting plasma glucose: > 5.6 mmol/L or 
previously diagnosed type 2 diabetes.  
 The IDF strongly recommends an OGTT. This is not a 
prerequisite to define the presence of the syndrome.
The WHO and the NCEP ATP III definitions of metabolic 
syndrome which are summarized in Table 2 pre-date the more 
recent IDF definition whcih has more stringent criteria and 
lower thresholds.
As Kahn rightly insists, the purpose of describing any 
syndrome is to inform medics – the ones actually dealing with 
patients – with regards to the necessary actions that need to be 
taken to provide control/cure.3  Without this provided guidance, 
there is a good ‘chance’ that the action taken would possibly be 
different.  
The clinical relevance 
of the metabolic syndrome
Our aim as physicians, especially in primary care is, from the 
outset, to do no harm and from then on take a holistic approach 
to our patients’ care.  
As physicians, the true value of any knowledge attained 
can only be calculated by its relevance to our practice which, 
at the end of the day, boils down to the benefits gained by our 
patients by the application of said information “…after all, 
the fundamental purpose of a medical label (diagnosis) is to 
inform physicians and/or patients to take (or not take) action 
that would otherwise be different”.3 Is identifying patients with 
metabolic syndrome clinically relevant? 
Blaha and Elasy scanned the National Library of Medicine’s 
Medline database for human studies published since 1988 
looking up various versions of describing metabolic syndrome/
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syndrome X/insulin resistance syndrome/dysmetabolic 
syndrome and the full text of over four hundred articles 
incorporating metabolic syndrome either as a variable or end-
point were grouped according to the definition the respective 
studies opted to adopt.4  It was concluded that, categorically 
two main perspectives were taken when it came to describing 
the metabolic syndrome:
1. the pathophysiological perspective 
2. the clinical epidemiological perspective.
The first perspective deals mainly with the sequelae of insulin 
resistance – atherogenic dyslipidaemia, hypertension, impaired 
glycaemia, pro-inflammatory state/endothelial dysfunction, 
prothrombotic state, disordered fat metabolism, fatty liver, 
abnormal uric acid metabolism and, also, abnormal ovarian 
androgen secretion.  The clinical epidemiological perspective, on 
the other hand, seeks to group related metabolic risk factors and 
to use this grouping in predicting future risk of cardiovascular 
disease and to stratify patients accordingly.  Cardiovascular 
disease is definitely the leading cause of premature, sudden 
and yet, preventable, deaths in many European populations. 
The implementation of evidence-based, preventive strategies 
would avert the majority of premature coronary heart disease 
world-wide. 
Wannamethee et al. questioned the role of diagnosing 
metabolic syndrome over using the Framingham Risk Score as 
predictors of coronary heart disease, stroke and type 2 diabetes 
mellitus in middle aged men.5 It was concluded that metabolic 
syndrome, as defined by the National Cholesterol Education 
Programme (NCEP), is associated with a significant increase in 
risk of coronary heart disease, stroke and type 2 diabetes mellitus 
and is a far stronger predictor of type 2 diabetes than of coronary 
heart disease and stroke.  Establishing a diagnosis of metabolic 
syndrome, did not imply improved prediction of coronary heart 
disease but it did identify those individuals predisposed to either 
cardiovascular disease or type 2 diabetes mellitus and hence may 
serve as a ‘simple’ clinical approach to identifying patients for 
clinical intervention to reduce cardiovascular disease and risk 
of type 2 diabetes mellitus. 
Sundström et al hypothesized that the presence of the 
metabolic syndrome, applying World Health Organisation 
(WHO) and NCEP definitions, increases the subsequent risk of 
total and cardiovascular mortality.6  It was also assumed that the 
prognostic impact of the metabolic syndrome may vary with age. 
In their community-based cohort study of men with a maximum 
32.7 year of follow-up, the metabolic syndrome was found to be 
an independent risk factor in middle age (follow up from the 
age of fifty) for both total and cardiovascular mortality, when 
established risk factors for cardiovascular disease were taken 
into account.  In fact, results showed a 40-60% increased risk 
for total and cardiovascular mortality in such circumstances. 
The syndrome, however, did not consistently predict adverse 
outcomes in elderly men (follow up from seventy years of age). 
This finding is quite surprising as it was precisely in this group 
of older individuals that the WHO definition’s criterion of 
microalbuminuria was actually applied.  Microalbuminuria is 
known to be generally the first clinical sign of renal dysfunction 
in diabetes mellitus resulting from endothelial dysfunction 
which is not necessarily confined to the kidney rendering the 
individual at an ever-increasing cardiovascular risk.
Managing the metabolic syndrome
The key features that are generally acknowledged to occur 
in the metabolic syndrome:
1. certain metabolic factors seem to occur together at a 
greater frequency than could be put down solely to chance
2. these same factors – taken alone or in combination – are 
associated with an increased risk for cardiovascular 
disease and diabetes
3. there is no definitive treatment for the syndrome.
Considering all this, dealing with metabolic syndrome, 
from a practical point of view involves screening for as many 
cardiovascular risk factors possible – perhaps taking central 
obesity as such a risk factor and attempting to measure abdominal 
Table 1: Ethnicity-related values 
for Waist Circumference indicating Central Adiposity
           Waist Circumference
 Males (cm) Females (cm)
Europids > 94  > 80
South Asians > 90 > 80
Chinese > 90 > 80
Japanese > 85 > 90
Table 2: WHO and NCEP ATP III definitions 
of the metabolic syndrome
WhO NCEP ATP III
Insulin resistance  At least three of the 
in the form of either: following 5 criteria:
• Type II DM • Waist circumference:
• Impaired fasting glucose  men ≥ 102 cm
• Impaired glucose tolerance  women ≥ 88 cm
   • Triglycerides 
Plus any 2 of the following:  ≥ 1.69 mmol/L
• Hypertension  • HDL cholesterol  
 (≥ 140/90mmHg)  < 1 mmol/L in males and
• Plasma triglycerides   < 1.3 mmol/L in females
 ≥ 1.7 mmol/L  • Hypertension 
 or HDL cholesterol   ≥ 130/85 mmHg or on
 < 0.9 mmol/L in men   antihypertensive
 or < 1.0 mmol/L in females.  medication
• BMI > 30 kg/m2 • Fasting glucose
• Microalbuminuria   ≥ 6.1 mmol/L
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girths and then advising the necessary lifestyle modifications. 
The NCEP concludes that most of the management will indeed 
consist of instituting TLC – therapeutic lifestyle changes. 
These lifestyle changes include weight loss and maintaining 
ideal weight once attained, changes to diet and increasing 
exercise.  TLC requires the patient’s commitment so as doctors 
it is important that we convince our patients that they are at an 
increased risk for preventable cardiovascular disease and there 
is something that can be done about it if they choose to.  
Whilst the practicality of TLCs may be questioned, it 
definitely is dependent on a number of factors – both patient 
and doctor centred.  Some patients may prove enthusiastic and 
receptive to these changes; others may find that bad habits die 
hard.  Results of a randomized trial of lifestyle modification 
and pharmacotherapy for obesity underscored the importance 
of prescribing weight-loss medication in combination with, 
rather than instead of, lifestyle modification.7  It was found 
that combination of group lifestyle modification counseling and 
pharmacotherapy resulted in approximately twice as much total 
weight loss achieved by groups receiving either pharmacotherapy 
alone (sibutramine was administered in this study) or lifestyle 
modification counseling alone.  Active participation, e.g. keeping 
a diary of daily food intake, reflected a direct proportion of 
weight loss throughout assessment.  There was also a significant 
increased weight loss in the group prescribed sibutramine and a 
limited number of encounters with their primary care physician 
in those on sibutramine only.  Thus, it appears there is scope 
for further research to identify effective methods of providing 
lifestyle counseling in primary care.
Risk calculation and guidelines regarding treatment 
initiation are available, tried and tested. Risk assessment models 
such as those derived from Framingham data and the, perhaps 
more locally relevant, Systemic Coronary Risk Evaluation 
(SCORE) system can be used to establish risk of cardiovascular 
disease.8,9 The latter is applicable even if a patient is already 
on treatment.  This is where the physician can be offering 
most to his patient by using evidence-based and structured 
outlines to screen for the most relevant of risk factors efficiently, 
knowing when it is important to initiate treatment and be able 
to illustrate it to the patient who will then, hopefully be, in a 
better position to play a more-than-passive role in his own 
care.    The SCORE risk charts enable the doctor to calculate 
not only a patient’s total CVD risk but also his relative CVD risk 
(comparing with a normotensive, normolipidaemic age- and 
sex- matched counterpart) along with the impact of intervention 
(e.g. stopping smoking) on the total risk.  Even in dealing with 
young adults – who are at a low absolute risk – the SCORE 
charts provide means of visualising increasing lifetime absolute 
risk by following the table upwards. Hence, these SCORE charts 
act to reinforce the relevance of breaking bad habits early and 
opting to adopt a healthy lifestyle.  The NCEP’s third report on 
detection, evaluation and treatment of high blood cholesterol 
in adults has put persons with diabetes without coronary heart 
disease to the risk level of coronary heart disease equivalent.10 
It takes into consideration that most of these persons display 
multiple risk factors so the metabolic syndrome is considered 
as a secondary target of therapy and advises management with 
a two-fold objective:
1. the reduction of underlying causes
2. treatment of associated lipid and non-lipid risk factors.
A fasting total lipid profile (including triglyceride, low 
density lipoprotein and high density lipoprotein levels) and 
fasting blood glucose ± an oral glucose tolerance test can hence 
be seen to be very relevant investigations in screening for 
cardiovascular risk factors.  The Federation itself acknowledges 
the importance of the oral glucose tolerance test in cases 
of impaired fasting glucose.   Hence, it is the primary care 
physician who would be able to make most effective use of 
this investigation. A diagnosis of impaired glucose tolerance 
is associated with a significantly increased risk of premature 
mortality and cardiovascular disease.11 
The importance of the prevention of coronary heart disease 
in clinical practice basing intervention on an assessment of the 
individual’s total risk burden rather than on the level of any 
particular risk factor making use of evidence-based tools such 
as SCORE is widely recognized.8 
The primary care physician looking after JS should 
emphasise that:
•	 Diet needs to be a varied one and ideal body weight, 
once attained, is maintained by adjusting calorific 
intake.  Whilst encouraging the consumption of fruit 
and vegetables, whole grain cereals and bread, low fat 
dairy products, fish and lean meat total fat intake should 
account for < 30% of energy intake.  
•	 Increasing physical activity has its obvious advantages. 
European guidelines have set their goal at half an hour of 
physical activity on most days of the week: 4 to 5 times 
weekly at up to 75% of his maximum heart rate.
•	 Blood pressure readings of persistently ≥140/90 mmHg, 
excluding diabetes mellitus where targets will be lower, 
imply drug treatment needs to be instituted along with 
lifestyle modification opting for a drug that not only 
brings JS’ BP into a normal range but that has also been 
proven to reduce cardiovascular morbidity and mortality.
•	 An oral glucose tolerance test as this is the only way 
impaired glucose tolerance can be diagnosed.  
•	 Assessment of total cholesterol (TC) and Low density 
lipoprotein (LDL) levels aiming at keeping TC < 5 mmol/
L and LDL at < 3 mmol/L.
The European Guidelines on CVD Risk Prevention state that
high total risk patients are those:9
•	 with established CVD
•	 asymptomatic patients with:
•	 multiple risk factors resulting in ≥ 5% ten year risk now or 
if extrapolated to age 60y
•	 markedly elevated single risk factors:
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•	 total cholesterol ≥ 8mmol/L 
•	 LDL cholesterol ≥ 6 mmol/L
•	 blood pressure ≥ 180/110 mmHg
•	 type II diabetes and diabetes type I with 
microalbuminuria.
High risk patients need to be treated.  There is no real 
relevance of applying risk stratification in such cases.  Treating 
with low-dose aspirin, a statin and an ACE-inhibitor is nearly 
an inevitable matter in these high risk patients.
Conclusion
It is undeniable that there are modifiable risk factors for 
cardiovascular and coronary heart disease which the physician 
needs to identify and treat accordingly.  In a joint statement 
from the American Diabetes Association and the European 
Association for the Study of Diabetes clinicians are advised:12 
•	 To screen adults known to have any CVD risk for other 
CVD risk factors.
•	 When risk variables are found to be out of recommended 
ranges, lifestyle modification should be advised. However 
when these are diagnostic of frank disease (e.g. FBG ≥ 7.0 
mmol/L) management should be initiated according to 
the relevant established guidelines.
•	 All risk factors for cardiovascular and coronary heart 
disease warrant individual and aggressive treatment.
•	 To avoid labelling of patients with the term metabolic 
syndrome as it is yet unclear that the syndrome does 
indeed carry a greater risk than its components and as 
there is no defined pharmacological treatment for it.
Every effort should be made to identify, minimise and treat 
cardiovascular risk in total. 
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